

Curriculum Vitae

Name: Thomas van Overeem Hansen (TvOH)

Date and place of birth: May 6th, 1968, Frederiksberg, Denmark

Nationality: Danish

Sex: Male

E-mail. tvoh@rh.dk

Education and academic degrees:

1988: Graduated from Roskilde Gymnasium

1993: B.Sc. in Chemistry, University of Roskilde

1997: M.Sc. in Biochemistry, University of Copenhagen

2001: Ph.D. at the University of Copenhagen

2016: Clinical Laboratory Geneticist

Employment:

01-02-1998 to 01-04-2001: Klinisk assistent and Ph.D.-student, Department of Clinical Biochemistry, Rigshospitalet

01-04-2001 to 01-04-2004: Post-doc scholarship from the Danish Medical Research Council, Department of Clinical Biochemistry, Rigshospitalet

01-04-2004 to 31-12-2011 : Molecular biologist, Department of Clinical Biochemistry, Rigshospitalet

01-01-2012 to 28-02-2018: Chief biochemist, Center for Genomic Medicine, Rigshospitalet

01-03-2018 to 28-02-2021: Senior scientist, Department of Clinical Genetics and Department of Paediatrics and Adolescent Medicine, Rigshospitalet

01-03-2021 to 01-04-2022: Senior scientist, Department of Clinical Genetics, Rigshospitalet

01-04-2022 Professor, Department of Clinical Medicine, University of Copenhagen, and Department of Clinical Genetics, Rigshospitalet

Management experience:

Chief Biochemist from 2012 to 2018. Leader of several research projects involving supervision of Ph.D.-students, master- and bachelor-students.

Participant in the Capital Region of Denmark's "management of employees" in 2014.

Quality manager from 2012 to 2018 and responsible for four DANAK site visits.

Discipline involvement:

2005 - 2017 Member of the Danish VHL-group

2006 - 2017 Secretary in the Genetic Council of Danish Breast Cancer Cooperative Group (DBCG)

2007 - 2008 Member of DANAK's working group in Medical Genetics

Curriculum Vitae

2009 - Member of Danish Pediatric Hematology and Oncology (DAPHO)
2015 - Initiated the national Danish Breast Cancer Variant Classification Group (DBKG)
2018 - Member of Danish Society of Medical Genetics (DSMG)
2018 - Member of the National Danish Breast Cancer Variant Classification Group (DBKG)
2019 - Member of the National Danish Colorectal Cancer Variant Classification Group (DCKG)
2019 - Member of InSiGHT MMR variant interpretation committee (VIC), and Biocurator from 2021
2020 - Member of ClinGen APC variant curation expert panel (VCEP), and Biocurator from 2022
2020 - Member of DSMGs cancer gene expert panel (onkogenet)
2021 - Member of NGCs national expert panel for children and adolescents with cancer
2021 - Member of the Genetic Council of Danish Breast Cancer Cooperative Group (DBCG)
2022 - InSiGHT Hereditary Colorectal Cancer/Polyposis Variant Curation Expert Panel, MUTYH

Supervision and education:

TvOH has supervised/co-supervised 6 bachelor -, 6 master -, and 5 PhD-thesis students.

Moreover, TvOH has been censor/opponent/chair at bachelor thesis (31) -, master thesis (22) - and Ph.D. thesis (4) defenses, at Faculty of Science and Faculty of Health and Medical Sciences, University of Copenhagen, Odense University, or Karolinska University.

Pregraduate teaching:

2008 – 2009: Molecular biomedicine, University of Copenhagen, Theoretical Pathophysiology, journal club, lectures (2)

2021 and onwards: Medical students, 3-5 lectures per semester

Postgraduate teaching:

2008 - 2009 Continuing education of physicians in Region Zealand, Genetic markers, lectures (2)

2012 and 2015 Clinical Geneticists, A-course in oncogenetics, lectures (2)

2022 Master of Personalized Medicine, Wetlab omics, functional studies, lectures (1)

Peer review – Scientific articles:

TvOH has reviewed manuscripts for a variety of different journals (>50), including *Clinical Cancer Research* (AACR), *International Journal of Cancer* (Wiley), *Human Mutation* (OUP) and *Cancers* (MDPI).

Peer review – Funding:

TvOH have reviewed project grants from the UK's Medical Research Council, South African Medical Research Council and the Icelandic Research Foundation.

Selected research support:

2011: 1.500.000 Dk, Research Foundation of Capital Region of Denmark (Co-applicant)

2013: 900.000 Dkk, Rigshospitalets Research Foundation (Co-applicant)

2015: 500.000 Dkk, Research Foundation of Capital Region of Denmark (PI)

2020: 1.125.000 Dkk, Læge Carl Emil Friis og Hustru Olga Doris Friis Legat (Associate Investigator)

2020: 300.000 Dkk, Danish Cancer Society (Associate Investigator)

Curriculum Vitae

2021: 584.000 Dkk, OUH and Rigshospitalets Research Foundation (Co-applicant)

2022: 21.593.205 Dkk, Innovation Fund Denmark (Co-applicant)

2023: 1.600.000 Dkk, Danish Childhood Cancer Foundation (Associate Investigator)

International scientific collaborations:

Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA): CIMBA is a collaborative group of researchers working on genetic modifiers of cancer risk in BRCA1 and BRCA2 mutation carriers. The aim of CIMBA is to provide sufficient sample sizes to allow large scale studies in order to evaluate reliably the effects of genetic modifiers. TvOH initiated the East-Danish participation in 2007 by establishing Copenhagen Breast Cancer Study (CBCS). Has participated in the following CIMBA meetings: 2007 (Copenhagen), 2009 (Amsterdam), 2010 (Cambridge), 2010 (Riva del Garda), 2011 (Stockholm), 2012 (Paris), 2012 (Quebec), 2013 (El Escorial), 2014 (Leuven), 2015 (Porto), 2017 (Limassol), 2019 (Springdale), 2020 (Lillehammer), 2022 (Leiden), 2023 (Vienna).

Evidence-based Network for the Interpretation of Germline Mutant Alleles (ENIGMA): ENIGMA is an international consortium of investigators focused on determining the clinical significance of sequence variants in BRCA1, BRCA2 and other known or suspected breast and/or ovarian predisposition genes, to provide this expert opinion to global database and classification initiatives, and to explore optimal avenues of communication of such information at the provider and patient level. TvOH participated in the founding meeting in Amsterdam (2009) and has been a member since. Has participated in the following meetings: 2010 (London), 2010 (Milan), 2011 (Stockholm), 2012 (Paris), 2012 (Quebec), 2013 (Madrid), 2014 (Leuven), 2015 (Porto), 2017 (Limassol), 2019 (Springdale), 2020 (Virtual meeting), 2021 (Virtual meeting), 2022 (Leiden), 2023 (Vienna).

COMPLEXO (breast cancer exome consortium): COMPLEXO aims to identifying the missing heritability of breast cancer via next generation collaboration. TvOH participated in the founding meeting in 2012 and has been a member since.

CONFLUENCE: Confluence aims to build a large research data resource of approximately 300,000 breast cancer cases and 300,000 controls for multi-ancestry genome wide association studies (GWAS) to discover variants for breast cancer risk overall and by subtype, develop multi-ancestry polygenic risk scores for personalized risk assessment and to discover variants for breast cancer survival, pharmacogenomics, and second cancers. CONFLUENCE builds on data from CIMBA and other consortia, and therefore TvOH has participated since the start in 2018.

The International Society for Gastrointestinal Hereditary Tumours Incorporated (InSiGHT): InSiGHT is a multidisciplinary scientific organisation, whose mission is to improve the care of patients and families worldwide with any hereditary condition resulting in gastrointestinal tumours. TvOH has been a member since 2015.

International Mismatch Repair Consortium (IMRC): IMRC aims to conduct comprehensive penetrance analyses on large, ethnically heterogeneous samples of persons/families segregating mutations in MMR genes. TvOH has been a member since 2013.

Curriculum Vitae

Publications:

TvOH has published 189 articles, including 177 original research papers and 12 reviews in peer-reviewed international journals. The publications have been cited 9102 times (January 1th, 2024, Web of Science). H-index: 52 (January 1th, 2024, Web of Science). TvOH is first/last/corresponding author on ~22% of his papers.
